We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Piller, in terms of a balanced view I take an opposite position. Long term holder for many years. I've not ever sold. I recognise the investment the business has made in the technology and the markets the business is trying to access. It has one of the only truly portable PCR machines on the market, the others are Roche and Cepheid. Genedrive is targeting a mixture of diseases, each is worth a multiple to todays share price. We now have 3 tests on market, HCV, AIHL and the DOD with the forth revised TB test also coming on line. The brokers target price was 95p and revised down to 60p to take into account the delayed sales for HCV. We are sat at 25p. There is an argument to say we are undervalued at todays price, my opinion is that we are. Then you have COVID19. If you allow £10 per test even a small lab at 1,000 samples per day would generate £3.5m per year in turnover. We are talking about up to 250k per day, almost £1Bn, in the UK... What Genedrive offers IF they are successful is the lab based test and the same test run on an ultra portable unit. So agree it is an IF, but they have delivered before and it's in their sweet spot so you have to have confidence. Genedrive is already in market and selling into the NHS. Let's say they have 10% of the £1bn market. Thats £100m of sales in the UK. The numbers really do put a massive upside to the share. There will be a number of UK suppliers, it makes sense in terms of continuity of supply. Genedrive will be in the mix.
Sorry for the delay scart. People haven’t been saying buy buy buy? Maybe not them exact words but saying this is going £1-£2 don’t miss out, get in quick, and all the rest of the pages of ramps over the last week all means the same to me.
I think a lot of people have just jumped in looking at the rise, with the boards encouragement thinking we have a quick money-making scheme, to one sense there is ,if all goes to plan, but all plans aren’t straight forward.
This is a very illiquid stock with a company who have small limited funds and poor sales. Grants running out, which is a time consuming job in itself to sort.
Yes there are positives but also negatives which some haven’t even looked at.
Product sales: Sales of device and assay (HCV-ID and DoD product) were significantly below forecasts (by -£0.52m, due in part to the delay in fulfilling the DoD order) at ca.£0.3m and represented a 58% decrease on the comparable period last year. The majority of the £0.3m was composed of DoD sales, meaning that there has been little to no growth in HCV-ID sales.
? Grant income: Grant income of £0.3m (including £0.2m associated with TB development work) was slightly below forecasts, but the decline on the prior period was anticipated, as the grant-funded TB and RNR-1 development programmes move towards completion.
? Administration costs: In line with the decline in product sales and tight control of costs, administration costs (COGS and SGA) were below forecasts by £0.36m at -£0.90m.
? Net cash/(debt): Underlying operating profit fell 27% on the prior period to -£2.57m (-£2.02m). Combined with an unexpected working capital requirement, GDR ended the period with cash of £3.5m, which was below forecasts by -£1.3m. Debt in the form of convertible bonds is now being carried at £9.3m, resulting in a net debt position of -£5.8m on 31 December 2019.
I am invested but half to what I initially jumped in with. When the time comes we get the news all systems go, I will double up. Until then I will wait and watch. All just my opinion, just thought this board was very one sided.
Good luck with your investments.
Piller. I think we should also have balanced views, some might be optimistic and others not so. I haven't really seen people saying Buy Buy Buy. Some naturally have belief in the company and others might be more cautious as to the potential for the sp retreating on no news. There's been some good info shared here the last week or so, particularly from BigBench.
I see you tend to only come on here to tell people to stop ramping or say we should have a placing. Can you share some decent information? If you're invested then I assume you'd want to have a positive view of the company or else what's the point, you may as well cut your losses - and it is possible to be both realistic and positive at the same time.
However, I'm also always happy to hear both sides. If there's something we should be aware of then it's good to share without people shouting ramp or deramp - there's no benefit in either of those comments? It's quite evident when people spout this and investors can decide for themselves what to believe in. But with news imminent given the previous RNSs and in my view positive news, what do you think is not rosie about it? Are you going to suggest a placing at 9p again? I mean given the support the government is giving businesses through funding, the potential near future sales and the large Pharmas coming in to push testing forward, I think a placing is unlikely - if they needed it then they could get loaned the money at a cheap rate, and so doesn't really fit the current situation, but that's my view of course and you're naturally welcome to yours.
The potential numbers speak for themselves as well as the unique product which doesn't need a lab & 3 days to get results.. do you realise how that will benefit the poorest countries with no labs within 100's of miles. No begin letters need here just look and the product and the world wide demand that should be enough for anyone to help them make investment decisions.
See, my point exactly. If anything it puts people off investing as some of these post’s sound like begging letters.
Tbh I believe out of all the corona investments this one has the most upside now . Expecting big moves here over the coming weeks
Need to take a step back and look at this properly, don’t get sucked in by the constant post after post of buy buy buy.
Read previous rns’s it’s not all Rosie.
Looking at the 5day chart it’s on a downward trend will see 20p again soon as a level.